The Drug-Induced Respiratory Disease Website

III - Myocardial ischemia - Coronary artery disease

III.a

Coronary artery disease (acute) - Myocardial ischemia/infarction

1

Evidence level

low

XI - Pulmonary vasculopathies

XI.a

Pulmonary arterial hypertension

1

Evidence level

low

XII - Pericardial involvement

XII.n

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

1

Evidence level

low

XIV - Pleural involvement

XIV.a

Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)

1

Evidence level

low

XVI - Hemorrhage - Bleeding - Hematoma(s)

XVI.e

Alveolar hemorrhage (AH), diffuse AH (DAH)

1

Evidence level

low

XVI.i

Hemoptysis

1

Evidence level

low

XVIII - Aortic involvement

XVIII.c

Arterial (aorta, limb) vasoconstriction and/or ischemia, acute

1

Evidence level

low

XX - Vasculitis

XX.d

Vasculitis, pulmonary (w/wo AH), extrathoracic, or systemic: ANCA-positive

3

Evidence level

probable

XXVIII - Large airway involvement

XXVIII.p

Nasal, palatal and/or pharyngeal pathology

2

Evidence level

possible

XXXI - Eye catchers

XXXI.h

Midline destructive lesions

2

Evidence level

possible

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.s

Dual MPO-/PR3-ANCA systemic disease/vasculitis or pseudovasculitis

1

Evidence level

low

XXXVI.t

Pneumorenal syndrome (w/wo ANCAs)

1

Evidence level

low

XXXVI.u

Pulmonary vasculitis or capillaritis

1

Evidence level

low

XXXVIII - Miscellaneous - Varia

XXXVIII.d

Death following exposure or poisoning

1

Evidence level

low

XXXVIII.q

Myopathy-Myositis-Polymyositis

1

Evidence level

low

XXXVIII.y

Neutropenia, agranulocytosis (w/wo infection/sepsis)

3

Evidence level

probable